Tech Company Financing Transactions
Immunis.AI Funding Round
On 10/2/2021, Immunis.AI raised funding from Savitr Capital and private investors.
Transaction Overview
Company Name
Announced On
10/2/2021
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
Savitr Capital (Lead Investor)
Proceeds Purpose
Funding will support further validation and commercialization of the company's first molecular test in prostate cancer and will also be used to expand development of new tests in breast, colon, lung cancer and other cancers.
Company Information
Company Status
Private & Independent
Industry
Healthcare IT
Mailing Address
1310 N Stephenson Hwy. 101
Royal Oak, MI 48067
USA
Royal Oak, MI 48067
USA
Phone
Website
Email Address
Overview
Immunis.AI is a privately held immunogenomics company committed to making a global impact by empowering patients and their physicians with actionable information for disease detection and management.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Christopher Thibodeau
Chief Medical Officer
Kirk Wojno
Chief Scientific Officer
Leander Van Neste
VP - Bus. Development
Geoffrey Erickson
Browse more venture capital transactions:
Prev: 10/2/2021: avonow.com venture capital transaction
Next: 10/2/2021: Found Health venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs